Radix Pharmaceuticals, Inc.

Potomac, MD 20854

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $4.43MM
First Award Date 04/01/05
Most Recent Award Date 06/01/13

Key Personnel

Last Name Name Awards Contact
Zhu Shuren Zhu 12

12 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/13 - 05/31/14

DESCRIPTION (provided by applicant): The proposed research focuses on the development of novel therapeutic agents for the prevention and treatment of malaria caused by P. falciparum. A previous Phase I project has discovered novel molecules with potent antimalarial activity against both sensitive and multidrug resistant malaria strains in some i...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/12 - 05/31/13

DESCRIPTION (provided by applicant): The proposed research focuses on the development of novel therapeutic agents for the prevention and treatment of malaria caused by P. falciparum. A previous Phase I project has discovered novel molecules with potent antimalarial activity against both sensitive and multidrug resistant malaria strains in some i...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/01/12 - 01/31/14

DESCRIPTION (provided by applicant): This project focuses on the development of a novel therapeutic agent for preventing and treating P. falciparum malaria. A two-year Phase I research has discovered novel molecules with potent antimalarial activity against both sensitive and resistant malaria strains in rodent models. Lead compounds are low in ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/05/11 - 01/31/12

DESCRIPTION (provided by applicant): This project focuses on the development of a novel therapeutic agent for preventing and treating P. falciparum malaria. A two-year Phase I research has discovered novel molecules with potent antimalarial activity against both sensitive and resistant malaria strains in rodent models. Lead compounds are low in ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 08/01/09 - 07/31/11

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated and purified two natural products from the leaves of Carica papaya L. The chemical structures...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 02/01/09 - 07/31/10

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated and purified two natural products from the dried root barks of Ocimum sanctum Linn. The chemi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 08/15/08 - 07/31/09

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated and purified two natural products from the leaves of Carica papaya L. The chemical structures...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 02/01/08 - 01/31/09

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated and purified two natural products from the dried root barks of Ocimum sanctum Linn. The chemi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 08/01/07 - 07/31/08

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. SBIR Phase I research and additional work at Radix Pharmaceuticals have demonstrated that some novel febrifugine analogues are p...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 03/01/07 - 02/29/08

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. falciparum malaria. Radix Pharmaceuticals has isolated and purified two natural products from the roots and rhizomes of Nardostachys chinensis Batal...

Load More